Stifel Maintains Hold on MEI Pharma, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a 'Hold' rating on MEI Pharma (NASDAQ:MEIP) and lowers the price target from $10 to $9.
September 27, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst Stephen Willey maintains a 'Hold' rating on MEI Pharma and lowers the price target from $10 to $9.
The lowering of the price target by Stifel analyst Stephen Willey from $10 to $9 indicates a potential decrease in the stock price of MEI Pharma in the short term. This is likely to have a negative impact on the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100